Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

• DOI: 10.1016/j.kint.2016.10.005
• Publication Date: 2016-12-16T00:45:47Z
• Authors: Timothy H.J. Good...; H. Terence Cook; Fadi Fakhouri; Fernando C. Fervenza; Véronique Frémeau...; David Kavanagh; Carla M. Nester; Marina Noris; Matthew C. Pickering; Santiago Rodrígue...; Lubka T. Roumenina; Sanjeev Sethi; Richard J.H. Smith; Charlie E. Alpers; Gerald B. Appel; Gianluigi Ardissino; Gema Ariceta; Mustafa Arici; Arvind Bagga; Ingeborg M. Bajema; Miguel Blasco; Linda Burke; Thomas D. Cairns; Mireya Carratala; Vivette D. D'Agati; Mohamed R. Daha; An S. De Vriese; Marie-Agnès Drago...; Agnes B. Fogo; Miriam Galbusera; Daniel P. Gale; Hermann Haller; Sally Johnson; Mihály Józsi; Diana Karpman; Lynne Lanning; Moglie Le Quintrec; Christoph Licht; Chantal Loirat; Francisco Monfort; B. Paul Morgan; Laure-Hélène Noël; Michelle M. O'Sha...; Marion Rabant; Eric Rondeau; Piero Ruggenenti; Neil S. Sheerin; Jenna Smith; Fabrizio Spoleti; Joshua M. Thurman; Nicole C.A.J. van...; Marina Vivarelli; Peter F. Zipfel
• Keywords: Glomerulopathy; Eculizumab

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues management these 2 diseases were considered by global panel experts. Areas addressed included renal pathology, clinical phenotype assessment, genetic drivers disease, acquired treatment strategies. order to help guide clinicians who are caring for such patients, recommendations best strategies discussed at length, providing evidence base underpinning current options. Knowledge gaps identified prioritized research agenda was proposed resolve outstanding controversial issues.